Figure S2 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis

Key Points

• MAIN FINDING: PLT012 effectively boosts antitumor immunity against liver cancer and liver metastasis.
• KEY EVIDENCE: Treated HCC mouse models showed significant immune response enhancement with PLT012 therapy.
• APPROACH: The study utilized in vivo distribution assays in a mouse model of hepatocellular carcinoma (HCC).
• SIGNIFICANCE: This finding could advance treatment strategies for patients with liver cancer and improve survival rates.